Creative Medical Technology Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Creative Medical Technology Holdings, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with regulatory validation and large market targets, but minimal market cap and pre-profitability profile carry substantial execution risk. The company trades at a $7.87M market cap as of June 12, 2026, with significant stock price erosion (down 65.92% from its 52-week high). Analysts expect a.
What is Creative Medical Technology Holdings, Inc.'s industry? Creative Medical Technology Holdings, Inc. (creativemedtech.com) operates in Regenerative Medicine. AskCyborg classifies Creative Medical Technology Holdings, Inc. under Regenerative Medicine in its company registry.
Creative Medical Technology Holdings is a commercial-stage biotechnology company focusing on novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics. The company announced re...
Cyborg Score thesis
Early-stage biotech with regulatory validation and large market targets, but minimal market cap and pre-profitability profile...
Read the full analyst-debate transcript →Get the Latest Creative Medical Technology Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCreative Medical Technology Holdings, Inc. Overview
Pro stress-test →Creative Medical Technology Holdings is a commercial-stage biotechnology company focusing on novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics. The company announced regulatory approval in January 2026 for its BioDefense Inc. Burn Pit Initiative, enabling a national program to collect expanded molecular and cellular data from veterans affected by burn pit exposure. The company is pursuing AI-enabled regenerative medicine solutions addressing multi-billion-dollar market opportunities.
Strategic Profile
Pro stress-test →The Burn Pit Initiative is funded using existing partnerships (including Greenstone Biosciences), internal infrastructure, and prior vendor relationships to support AI-driven molecular modeling, iPSC development, and regenerative countermeasure work. CELZ-101 has received FDA Orphan Drug Designation for brittle Type 1 Diabetes, offering potential market exclusivity, with ongoing clinical trials in Type 1 Diabetes and chronic lower back pain representing multi-billion-dollar market opportunities. The company maintains a lean operational footprint with minimal dilution risk from near-term funding needs.
Competitive Landscape
Pro stress-test →CELZ competes in regenerative medicine and immunotherapy against larger, better-capitalized biotech firms. Direct competitors in stem cell therapeutics include Mesoblast, Fate Therapeutics, and Moderna (cell therapy division). The company's narrow market focus on orphan indications (brittle Type 1 Diabetes) and specialized applications (burn pit exposure recovery) positions it as a niche player with less head-to-head competition but limited addressable markets.
Industry Context
Creative Medical Technology Holdings, Inc. operates in Regenerative Medicine.
Key facts
Founded: Not specified in sources · Headquarters: Phoenix, US · Employees: 4 · Revenue: Not publicly disclosed · Market cap: $7.87M